Mario D. Aceto

In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

J. Lowe, M. Aceto, D. R. Compton, 1996, The Journal of pharmacology and experimental therapeutics.

Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.

J. Lowe, M. Aceto, B. Martin, 1996, The Journal of pharmacology and experimental therapeutics.

Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model.

M. Aceto, L. Harris, F. Carroll, 2005, European journal of pharmacology.

Etorphines: mu-opioid receptor-selective antinociception and low physical dependence capacity.

M. Aceto, L. Harris, E. Bowman, 1997, European journal of pharmacology.

Introduction of a 6-cyano group in 14-oxygenated N-methylmorphinans influences in vitro and in vivo pharmacological activities

M. Spetea, H. Schmidhammer, Valeria Follia, 2011, BMC Pharmacology.

Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.

J. Lowe, M. Aceto, B. Martin, 1995, European journal of pharmacology.